<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970292</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-103-034</org_study_id>
    <secondary_id>2016-003434-24</secondary_id>
    <nct_id>NCT02970292</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACADIA Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACADIA Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive
      placebo in the treatment of schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of adjunctive pimavanserin in the treatment of schizophrenia</measure>
    <time_frame>Approximately 14 weeks</time_frame>
    <description>Efficacy of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia measured with Positive and Negative Syndrome Scale (PANSS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Pimavanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + background antipsychotic, taken as two tablets, once daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin</intervention_name>
    <description>Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth</description>
    <arm_group_label>Pimavanserin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, taken as two tablets, once daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults patients, aged 18 years and above

          2. A clinical diagnosis of schizophrenia with a minimum duration of 1 year

          3. Has had equal to or less than 10 years of treatment with an antipsychotic

          4. The main background antipsychotic with which the subject is being treated must be one
             of the antipsychotics listed below:

               -  Aripiprazole

               -  Risperidone

               -  Olanzapine

               -  Lurasidone

               -  Cariprazine

               -  Brexpiprazole

               -  Asenapine

               -  Risperidone long-acting injection

               -  Aripiprazole long-acting injectables:

                    -  Abilify Maintena®

                    -  Aristada®

          5. Has had a partial but inadequate response to antipsychotic treatment

          6. Has a history of response to antipsychotic treatment other than clozapine

        Exclusion Criteria:

          1. Patient has a psychiatric disorder other than schizophrenia

          2. Patient has a history of resistance to antipsychotic treatment

          3. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular,
             respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical
             disorder, including cancer or malignancies, which would affect the patient's ability
             to participate in the program

          4. Patient has had a myocardial infarction in the last six months

          5. Patient is taking a medication or drug that prolongs the QT interval or has a history
             or symptoms of long QT syndrome

        Patients will be evaluated at screening to ensure that all criteria for study
        participation are met. Patients may be excluded from the study based on these assessments
        (and specifically if it is determined that their baseline health and psychiatric condition
        do not meet all pre-specified entry criteria).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Randy Owen, MD</last_name>
    <phone>215-809-2049</phone>
    <email>rowen@acadia-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dragana Bugarski-Kirola, MD</last_name>
    <phone>609-250-6903</phone>
    <email>dbugarski-kirola@acadia-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 18, 2016</lastchanged_date>
  <firstreceived_date>November 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
